Feasibility and Safety of Delivering a Ketone Drink to Comatose Survivors of Out-of-hospital Cardiac Arrest
1 other identifier
interventional
5
1 country
1
Brief Summary
Every year, efforts are made to resuscitate about 30,000 people when their hearts stop outside of the hospital environment ('out-of-hospital cardiac arrest'). Early damage to the brain due to 'oxygen starvation' (seemingly paradoxically) gets worse when blood flow is restored. Of the 6,350 survivors admitted to intensive care units, 46% die from brain damage, and half of those who survive suffer long-term brain damage. Apart from avoiding a high temperature, nothing has been found which can protect the brain or improve outcome. 'Ketones' are chemicals naturally produced in the body from fat during starvation. They act as an energy source, but also as regulators of metabolism, and appear to protect cells from damage when oxygen supplies are scarce, or when blood flow is restored. The investigators want to see whether a ketone drink will protect the brain after out-of-hospital cardiac arrest. The investigators will study 10 cardiac arrest patients, and participants will be given the ketone drink via a feeding tube (which is routinely passed into the stomach in such cases). The investigators shall check that the drink is absorbed, and measure the ketone levels in the blood. The investigators will also measure important aspects of blood chemistry (including pH and blood sugar) and collect data on brain (electrical recordings called 'EEG' and 'SSEP') and heart function (ultrasound scans or 'echocardiographs') - both of which it is hoped might improve - in order to demonstrate that this is possible if it is to be included in a subsequent large trial. The study will be scrutinised by world experts in the field, who have also helped design the study. If this pilot study is a success, the investigators will apply to a major grant body to fund an appropriately-powered randomised controlled trial to determine whether ketones improve neurological outcome and survival in these patients. Results will also allow similar studies to be planned in heart attack, stroke and traumatic brain injury.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Mar 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 12, 2017
CompletedFirst Posted
Study publicly available on registry
July 21, 2017
CompletedStudy Start
First participant enrolled
March 14, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 13, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
September 13, 2019
CompletedMay 14, 2025
May 1, 2025
1.5 years
July 12, 2017
May 9, 2025
Conditions
Outcome Measures
Primary Outcomes (11)
Change from baseline arterial blood gas values for pH
48 hours
Change from baseline arterial blood gas value for bicarbonate (mmol/L),
48 hours
Change from baseline arterial blood gas value for base excess (mEq/L),
48 hours
Change from baseline arterial blood gas value for glucose (mmol/L)
48 hours
Change from baseline arterial blood gas value for lactate (mmol/L)
48 hours
Change from baseline biochemistry laboratory results (full biochemistry panel including lipids, non-esterified fatty acids and serum insulin as per study protocol)
48 hours
Change from baseline haematology laboratory results (full blood count and coagulation profile as per study protocol)
48 hours
Time from arrival of participant to ketone drink administration (hh:mm)
24 hours
Number of participants receiving full course of ketone drink
As defined in study protocol: 25ml bolus followed after 1 hour by 47 hour infusion at 6 ml per hour
48 hours
Change from baseline serum troponin (ng/ml)
12 hours
Change from baseline serum neuron specific enolase (ng/ml)
48 hours
Secondary Outcomes (4)
Change from baseline level of plasma betahydroxybutyrate (mmol/L)
48 hours
Number of participants undergoing electroencephalogram as per protocol
72 hours
Number of participants undergoing somatosensory evokes potentials as per protocol
72 hours
Number of participants undergoing echocardiography as per protocol
72 hours
Study Arms (1)
Study group
EXPERIMENTALKetone ester drink to be administered by nasogastric tube. Initial bolus dose of 25 ml on enrollment. After 1 hour, begin 47 hr infusion at 6 ml per hour.
Interventions
Eligibility Criteria
You may qualify if:
- Aged 18 years or above
- Male or female
- Comatose survivors of out-of-hospital cardiac arrest, defined as return of spontaneous circulation for at least 5 minutes with a score of \<8 on the Glasgow Coma Scale
- For admission to intensive care unit for full, active treatment
You may not qualify if:
- Primary neurological or intracranial cause of cardiac arrest
- In-hospital cardiac arrest
- Over 4 hours from time of return of spontaneous circulation to enrollment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Barts & The London NHS Trustlead
- University College, Londoncollaborator
Study Sites (1)
Barts Heart Centre
London, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ajay Jain, MBBS MD
Consultant Cardiologist
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 12, 2017
First Posted
July 21, 2017
Study Start
March 14, 2018
Primary Completion
September 13, 2019
Study Completion
September 13, 2019
Last Updated
May 14, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share